ATNF 180 Life Sciences Corp

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).

As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company’s common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement.

About 180 Life Sciences Corp.

180 Life Sciences Corp. is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. The Company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

Investors:

Jason Assad

Director of IR

180 Life Sciences Corp



EN
14/03/2024

Underlying

ATNF180 Life Sciences Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 180 Life Sciences Corp

 PRESS RELEASE
Free
ATNF 180 Life Scienc...

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Pri...

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As indicated in the letter, Nasdaq determined that for 10 consecu...

March 14, 2024 1 EN
 PRESS RELEASE
Free
ATNF 180 Life Scienc...

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part...

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjust...

February 26, 2024 1 EN
 PRESS RELEASE
Free
ATNF 180 Life Scienc...

180 Life Sciences Engages Financial Advisor to Explore Strategic Alter...

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sale of assets, ...

December 4, 2023 1 EN
 PRESS RELEASE
Free
ATNF 180 Life Scienc...

180 Life Sciences Announces Review of Strategic Alternatives

180 Life Sciences Announces Review of Strategic Alternatives PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options. There is no assurance that the strate...

November 28, 2023 1 EN
 PRESS RELEASE
Free
ATNF 180 Life Scienc...

180 Life Sciences Corp. Announces Closing of $3 Million Public Offerin...

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately exercisable at an exerci...

August 14, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch